Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers
Qiu Rao(Indiana University School of Medicine), Liang Cheng(Brown University), Robert E. Emerson(Indiana University – Purdue University Indianapolis), David J. Grignon(Indiana University School of Medicine), Antonio López-Beltrán(Cordoba University), Muhammad T. Idrees(Indiana University School of Medicine), Rodolfo Montironi(Marche Polytechnic University), John N. Eble(Indiana University – Purdue University Indianapolis), Michael O. Koch(Indiana University School of Medicine), Lee Ann Baldridge(Indiana University School of Medicine), Xiao-jun Zhou(Nanjing University), Wenbin Huang(Nanjing Medical University), Shaobo Zhang(Indiana University – Purdue University Indianapolis), Sean R. Williamson(Cleveland Clinic)
Cited by 100
Related Papers
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
|Modern Pathology|2017|404
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
|Cancers|2021|289
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
|Cells|2020|256
The World Health Organization 2016 classification of testicular non‐germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel
|Histopathology|2016|236
Frequent <i>FGFR3</i> mutations in urothelial papilloma
|The Journal of Pathology|2002|189